Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR.

Ann Oncol. 2019 Aug 19. pii: mdz237. doi: 10.1093/annonc/mdz237. [Epub ahead of print] No abstract available.

PMID:
31430371
2.

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan.

Lo SN, Hong AM, Haydu LE, Ahmed T, Paton EJ, Steel V, Hruby G, Tran A, Morton RL, Nowak AK, Vardy JL, Drummond KJ, Dhillon HM, Mandel C, Scolyer RA, Middleton MR, Burmeister BH, Thompson JF, Fogarty GB.

Trials. 2019 Aug 5;20(1):477. doi: 10.1186/s13063-019-3555-5.

3.

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, Bataille V, Marmol VD, Dummer R, Harwood CA, Hauschild A, Höller C, Haedersdal M, Malvehy J, Middleton MR, Morton CA, Nagore E, Stratigos AJ, Szeimies RM, Tagliaferri L, Trakatelli M, Zalaudek I, Eggermont A, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6.

PMID:
31288208
4.

Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.

Findlay JM, Dickson E, Fiorani C, Bradley KM, Mukherjee S, Gillies RS, Maynard ND, Middleton MR.

Eur Radiol. 2019 Jul 5. doi: 10.1007/s00330-019-06310-9. [Epub ahead of print]

PMID:
31278574
5.

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL.

J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.

6.

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Morrell L, Wordsworth S, Schuh A, Middleton MR, Rees S, Barker RW.

BMC Health Serv Res. 2019 Mar 28;19(1):198. doi: 10.1186/s12913-019-4039-8.

7.

BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.

Herbert K, Binet R, Lambert JP, Louphrasitthiphol P, Kalkavan H, Sesma-Sanz L, Robles-Espinoza CD, Sarkar S, Suer E, Andrews S, Chauhan J, Roberts ND, Middleton MR, Gingras AC, Masson JY, Larue L, Falletta P, Goding CR.

Genes Dev. 2019 Mar 1;33(5-6):310-332. doi: 10.1101/gad.314633.118. Epub 2019 Feb 25.

8.

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.

de Santiago I, Yau C, Heij L, Middleton MR, Markowetz F, Grabsch HI, Dustin ML, Sivakumar S.

Int J Cancer. 2019 Aug 15;145(4):1125-1137. doi: 10.1002/ijc.32186. Epub 2019 Mar 18.

9.

Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.

Gray MD, Lyon PC, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DYF, Scott S, Anderson M, Goldin R, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.

Radiology. 2019 Apr;291(1):232-238. doi: 10.1148/radiol.2018181445. Epub 2019 Jan 15.

10.

Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery.

Findlay JM, Antonowicz S, Segaran A, El Kafsi J, Zhang A, Bradley KM, Gillies RS, Maynard ND, Middleton MR.

Eur Radiol. 2019 May;29(5):2490-2498. doi: 10.1007/s00330-018-5904-2. Epub 2019 Jan 14.

11.

The Circulating Transcriptome as a Source of Biomarkers for Melanoma.

Solé C, Tramonti D, Schramm M, Goicoechea I, Armesto M, Hernandez LI, Manterola L, Fernandez-Mercado M, Mujika K, Tuneu A, Jaka A, Tellaetxe M, Friedländer MR, Estivill X, Piazza P, Ortiz-Romero PL, Middleton MR, Lawrie CH.

Cancers (Basel). 2019 Jan 10;11(1). pii: E70. doi: 10.3390/cancers11010070.

12.

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS.

JAMA Oncol. 2019 Feb 1;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475. Epub 2019 Feb 14.

13.

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR.

Ann Oncol. 2019 Feb 1;30(2):317-324. doi: 10.1093/annonc/mdy500.

14.

VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors.

Cheng VWT, Soto MS, Khrapitchev AA, Perez-Balderas F, Zakaria R, Jenkinson MD, Middleton MR, Sibson NR.

Clin Cancer Res. 2019 Jan 15;25(2):533-543. doi: 10.1158/1078-0432.CCR-18-1889. Epub 2018 Nov 2.

PMID:
30389659
15.

Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?

Middleton MR.

Lancet Oncol. 2018 Nov;19(11):1424-1426. doi: 10.1016/S1470-2045(18)30753-8. Epub 2018 Oct 22. No abstract available.

PMID:
30361171
16.

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.

Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.

PMID:
30332497
17.

Single cell RNA-seq reveals profound transcriptional similarity between Barrett's oesophagus and oesophageal submucosal glands.

Owen RP, White MJ, Severson DT, Braden B, Bailey A, Goldin R, Wang LM, Ruiz-Puig C, Maynard ND, Green A, Piazza P, Buck D, Middleton MR, Ponting CP, Schuster-Böckler B, Lu X.

Nat Commun. 2018 Oct 15;9(1):4261. doi: 10.1038/s41467-018-06796-9.

18.

Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer.

Lyon PC, Winter H, Herbschleb K, Campo L, Carlisle R, Wu F, Goldin R, Coussios CC, Middleton MR, Gleeson FV, Boardman P, Sharma RA.

Radiol Case Rep. 2018 Sep 22;13(6):1259-1266. doi: 10.1016/j.radcr.2018.08.020. eCollection 2018 Dec.

19.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, Barker E, Newton-Bishop J, Middleton MR, Corrie PG.

Br J Cancer. 2018 Oct;119(7):793-800. doi: 10.1038/s41416-018-0179-6. Epub 2018 Jul 23.

20.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators.

Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229.

21.

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.

Lyon PC, Gray MD, Mannaris C, Folkes LK, Stratford M, Campo L, Chung DYF, Scott S, Anderson M, Goldin R, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.

Lancet Oncol. 2018 Aug;19(8):1027-1039. doi: 10.1016/S1470-2045(18)30332-2. Epub 2018 Jul 11.

22.

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Morrell L, Wordsworth S, Schuh A, Middleton MR, Rees S, Barker RW.

BMC Health Serv Res. 2018 May 31;18(1):393. doi: 10.1186/s12913-018-3162-2. Erratum in: BMC Health Serv Res. 2019 Mar 28;19(1):198.

23.

Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.

MacGregor TP, Carter R, Gillies RS, Findlay JM, Kartsonaki C, Castro-Giner F, Sahgal N, Wang LM, Chetty R, Maynard ND, Cazier JB, Buffa F, McHugh PJ, Tomlinson I, Middleton MR, Sharma RA.

Sci Rep. 2018 May 8;8(1):7265. doi: 10.1038/s41598-018-24232-2.

24.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR.

Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13.

25.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J.

J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):361. J Clin Oncol. 2019 Feb 1;37(4):361.

26.

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.

Findlay JM, Bradley KM, Gillies RS, Maynard ND, Middleton MR.

J Thorac Dis. 2017 Oct;9(10):3551-3552. doi: 10.21037/jtd.2017.09.54. No abstract available.

27.

Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.

Lyon PC, Griffiths LF, Lee J, Chung D, Carlisle R, Wu F, Middleton MR, Gleeson FV, Coussios CC.

J Ther Ultrasound. 2017 Nov 2;5:28. doi: 10.1186/s40349-017-0104-0. eCollection 2017.

28.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

29.

Societal preferences for adjuvant melanoma health states: UK and Australia.

Middleton MR, Atkins MB, Amos K, Wang PF, Kotapati S, Sabater J, Beusterien K.

BMC Cancer. 2017 Oct 17;17(1):689. doi: 10.1186/s12885-017-3673-y.

30.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Petrella TM, Robert C, Richtig E, Miller WH Jr, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J.

Eur J Cancer. 2017 Nov;86:115-124. doi: 10.1016/j.ejca.2017.08.032. Epub 2017 Oct 4.

31.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

32.

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.

Findlay JM, Bradley KM, Wang LM, Franklin JM, Teoh EJ, Gleeson FV, Maynard ND, Gillies RS, Middleton MR.

Br J Surg. 2017 Jun;104(7):947. doi: 10.1002/bjs.10611. No abstract available.

PMID:
28518409
33.

Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.

Dooley AJ, Gupta A, Middleton MR.

Target Oncol. 2017 Jun;12(3):385. doi: 10.1007/s11523-017-0483-8. No abstract available.

PMID:
28353073
34.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.

Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.

Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.

35.

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.

Findlay JM, Bradley KM, Wang LM, Franklin JM, Teoh EJ, Gleeson FV, Maynard ND, Gillies RS, Middleton MR.

Br J Surg. 2017 Mar;104(4):408-417. doi: 10.1002/bjs.10435. Epub 2017 Jan 17. Erratum in: Br J Surg. 2017 Jun;104(7):947.

PMID:
28093719
36.

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019. No abstract available.

37.

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.

Gupta A, Roberts C, Tysoe F, Goff M, Nobes J, Lester J, Marshall E, Corner C, Wolstenholme V, Kelly C, Wise A, Collins L, Love S, Woodward M, Salisbury A, Middleton MR.

Br J Cancer. 2016 Nov 8;115(10):1193-1200. doi: 10.1038/bjc.2016.318. Epub 2016 Oct 6.

38.

Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.

Findlay JM, Bradley KM, Wang LM, Franklin JM, Teoh EJ, Gleeson FV, Maynard ND, Gillies RS, Middleton MR.

J Nucl Med. 2017 Feb;58(2):266-275. doi: 10.2967/jnumed.116.176313. Epub 2016 Sep 15. Erratum in: J Nucl Med. 2017 May;58(5):852.

39.

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.

Kaisaki PJ, Cutts A, Popitsch N, Camps C, Pentony MM, Wilson G, Page S, Kaur K, Vavoulis D, Henderson S, Gupta A, Middleton MR, Karydis I, Talbot DC, Schuh A, Taylor JC.

PLoS One. 2016 Sep 14;11(9):e0162809. doi: 10.1371/journal.pone.0162809. eCollection 2016.

40.

Genetic susceptibility to Barrett's oesophagus: Lessons from early studies.

Findlay JM, Middleton MR, Tomlinson I.

United European Gastroenterol J. 2016 Aug;4(4):485-92. doi: 10.1177/2050640615611018. Epub 2015 Oct 13. Review.

41.
42.

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.

Aleksic T, Browning L, Woodward M, Phillips R, Page S, Henderson S, Athanasou N, Ansorge O, Whitwell D, Pratap S, Hassan AB, Middleton MR, Macaulay VM.

Front Oncol. 2016 May 2;6:98. doi: 10.3389/fonc.2016.00098. eCollection 2016.

43.

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR.

Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8.

44.

Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.

Middleton MR, Dalle S, Claveau J, Mut P, Hallmeyer S, Plantin P, Highley M, Kotapati S, Le TK, Brokaw J, Abernethy AP.

Cancer Med. 2016 Jul;5(7):1436-43. doi: 10.1002/cam4.717. Epub 2016 Apr 26.

45.

Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.

Findlay JM, Gillies RS, Franklin JM, Teoh EJ, Jones GE, di Carlo S, Gleeson FV, Maynard ND, Bradley KM, Middleton MR.

Eur Radiol. 2016 Oct;26(10):3519-33. doi: 10.1007/s00330-016-4227-4. Epub 2016 Feb 16.

PMID:
26883329
46.

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.

Dooley AJ, Gupta A, Middleton MR.

Target Oncol. 2016 Aug;11(4):557-63. doi: 10.1007/s11523-015-0410-9. Erratum in: Target Oncol. 2017 Jun;12 (3):385.

47.

Delayed oral toxicity from long-term vemurafenib therapy.

Lloyd-Lavery A, Hodgson T, Coupe N, Bond S, Shah K, Espinosa O, Payne MJ, Middleton MR, Matin RN.

Br J Dermatol. 2016 May;174(5):1159-60. doi: 10.1111/bjd.14457. Epub 2016 Mar 30. No abstract available.

PMID:
26853702
48.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.

49.

Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.

Malczewski A, Marshall A, Payne MJ, Mao L, Bafaloukos D, Si L, Pectasides D, Fountzilas G, Guo J, Gogas H, Middleton MR.

Cancer Med. 2016 Jan;5(1):17-23. doi: 10.1002/cam4.563. Epub 2015 Dec 8.

50.

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Ramcharan R, Aleksic T, Kamdoum WP, Gao S, Pfister SX, Tanner J, Bridges E, Asher R, Watson AJ, Margison GP, Woodcock M, Repapi E, Li JL, Middleton MR, Macaulay VM.

Oncotarget. 2015 Nov 24;6(37):39877-90. doi: 10.18632/oncotarget.5631.

Supplemental Content

Loading ...
Support Center